Monograph of Cotrimoxazole

Introduction/Overview

Cotrimoxazole, also known as co-trimoxazole or TMP‑SMX, constitutes a fixed-dose combination of trimethoprim and sulfamethoxazole. The drug has been a cornerstone of antimicrobial therapy since the 1960s, owing to its broad spectrum of activity and convenient oral formulation. Clinical relevance is underscored by its enduring role in the treatment and prophylaxis of Pneumocystis jirovecii pneumonia, urinary tract infections, and various Gram‑negative and Gram‑positive bacterial infections. The monograph is intended to provide a detailed pharmacological profile suitable for medical and pharmacy students, facilitating a comprehensive understanding of the agent’s therapeutic potential and safety considerations.

Learning objectives that may be derived from this chapter include:

• Describe the chemical classification and structural characteristics of cotrimoxazole.
• Explain the pharmacodynamic mechanism by which trimethoprim and sulfamethoxazole exert synergistic antibacterial effects.
• Summarize the key pharmacokinetic parameters influencing dosing regimens.
• Identify approved indications and common off‑label applications.
• Recognize major adverse effects, drug interactions, and special patient considerations.

Classification

Drug Classes and Categories

Cotrimoxazole is classified as a combination antibacterial agent. Individually, trimethoprim is a folate analog that functions as a dihydrofolate reductase inhibitor, while sulfamethoxazole belongs to the sulfonamide class, acting as a structural analog of para‑aminobenzoic acid (PABA). The combination is sometimes referred to as a synthetic antifolate regimen, given the sequential blockade of folate biosynthesis.

Chemical Classification

The molecular structure of trimethoprim is a 2,4‑dimethylpyrimidine derivative, whereas sulfamethoxazole features an anilide group linked to a sulfonamide moiety. Both compounds share a common pharmacophore that allows them to inhibit bacterial enzymes without significant cross‑reactivity with human homologs. The fixed ratio of 1:4 (trimethoprim to sulfamethoxazole) is maintained in commercial preparations to achieve optimal pharmacodynamic synergy.

Mechanism of Action

Pharmacodynamics

Trimethoprim selectively binds to bacterial dihydrofolate reductase (DHFR), thereby preventing the reduction of dihydrofolate to tetrahydrofolate. This step is essential for the synthesis of purines, thymidylate, and certain amino acids. Sulfamethoxazole competes with PABA for incorporation into dihydropteroate, a precursor in folate synthesis. By blocking two consecutive enzymes in the folate pathway, cotrimoxazole exerts a bactericidal effect that is markedly greater than either component alone.

Receptor Interactions

Trimethoprim demonstrates high affinity for bacterial DHFR, with dissociation constants (K_d) typically in the low nanomolar range. Sulfamethoxazole binds to the PABA binding site of dihydropteroate synthase (DHPS) with similar high affinity. The dual inhibition leads to depletion of intracellular tetrahydrofolate, causing a collapse of nucleic acid synthesis.

Molecular/Cellular Mechanisms

At the cellular level, the inhibition of DHFR and DHPS results in a rapid decrease in the available folate pool, which is essential for the synthesis of DNA, RNA, and proteins. Bacterial replication is arrested, and the intracellular accumulation of toxic intermediates induces cell death. The synergy between trimethoprim and sulfamethoxazole is dose‑dependent, with optimal therapeutic indices observed when the ratio of trimethoprim to sulfamethoxazole is maintained at 1:4. This ratio maximizes the suppression of resistant bacterial strains that may possess mutations in either DHFR or DHPS.

Pharmacokinetics

Absorption

Oral absorption is rapid and nearly complete when cotrimoxazole is administered in its standard tablet or liquid form. Peak plasma concentrations (C_max) are typically achieved within 1–2 hours post‑dose. Food intake does not significantly affect absorption; however, a high‑fat meal may marginally delay the time to peak concentration.

Distribution

Trimethoprim and sulfamethoxazole are distributed widely throughout body compartments. Trimethoprim achieves plasma protein binding of approximately 20–30%, whereas sulfamethoxazole demonstrates higher binding, around 50–60%. Both agents penetrate the central nervous system, with cerebrospinal fluid concentrations reaching 30–40% of plasma levels. Renal excretion is the primary route; hepatic metabolism is minimal for trimethoprim and negligible for sulfamethoxazole.

Metabolism

Metabolic transformation of cotrimoxazole is limited. Trimethoprim undergoes minor oxidation to 3‑hydroxytrimethoprim, which is further glucuronidated. Sulfamethoxazole is largely excreted unchanged; a small fraction is converted to a 2‑hydroxylated metabolite. Both metabolites retain negligible antimicrobial activity.

Excretion

Renal clearance dominates elimination, accounting for 70–80% of drug removal. The glomerular filtration rate (GFR) directly influences the half‑life; a 50% reduction in GFR may extend the t_1/2 of trimethoprim from approximately 10 hours to 20 hours. Urinary excretion is predominantly in the form of unchanged drug, with a minor contribution from conjugated metabolites.

Half‑Life and Dosing Considerations

The elimination half‑life (t_1/2) of trimethoprim is approximately 8–10 hours, while sulfamethoxazole’s t_1/2 ranges from 10 to 12 hours. The dosing interval is typically 12 hours for most indications, although a single daily dose is acceptable for prophylactic use. The standard adult dose for treatment is 1 mg/kg of trimethoprim (4 mg/kg of sulfamethoxazole) per dose, administered twice daily. Renal impairment necessitates dose adjustment: for patients with a creatinine clearance of 30–50 mL/min, the dose is reduced to 1 mg/kg of trimethoprim per dose once daily; for creatinine clearance <30 mL/min, therapy is generally avoided unless the benefit outweighs the risk.

Therapeutic Uses/Clinical Applications

Approved Indications

1. Pneumocystis jirovecii pneumonia (PCP) – both treatment and prophylaxis.
2. Urinary tract infections (UTIs) caused by susceptible organisms.
3. Otitis media, sinusitis, and pharyngitis when caused by susceptible pathogens.
4. Enteric fever, including typhoid and paratyphoid fevers.
5. Toxoplasmosis, particularly in immunocompromised patients.

Off‑Label Uses

Off‑label applications frequently encountered in practice include the management of:

• Acute bacterial meningitis (when combined with other agents).
• Complicated skin and soft tissue infections.
• Respiratory tract infections, especially in cystic fibrosis patients.
• Gastrointestinal infections caused by Clostridioides difficile (in combination with fidaxomicin).
• Prophylaxis of opportunistic infections in patients undergoing organ transplantation.

Adverse Effects

Common Side Effects

Gastrointestinal disturbances, such as nausea, vomiting, and diarrhea, are reported in up to 10% of patients. Cutaneous reactions, including maculopapular rashes, occur in approximately 1–2% of individuals. Photosensitivity, manifesting as sunburn‑like erythema, may arise during prolonged therapy. Hyperuricemia and mild elevations in serum creatinine are occasionally observed, particularly in patients with pre‑existing renal dysfunction.

Serious/Rare Adverse Reactions

Severe cutaneous adverse reactions, such as Stevens‑Johnson syndrome and toxic epidermal necrolysis, are rare but potentially life‑threatening. Hematologic toxicity, encompassing agranulocytosis, thrombocytopenia, and anemia, has been documented, particularly in patients with G6PD deficiency. Hemolytic anemia is a concern in this subgroup, with hemolysis occurring in up to 10% of affected individuals. Renal tubular acidosis, characterized by hyperchloremic metabolic acidosis, has been reported in association with chronic therapy. Rarely, severe hypersensitivity reactions leading to anaphylaxis may develop.

Black Box Warnings

While formal black box warnings are not currently issued for cotrimoxazole, regulatory agencies emphasize caution in patients with G6PD deficiency, severe renal impairment, and those at risk for hypersensitivity reactions. The potential for serious cutaneous reactions necessitates prompt discontinuation upon identification of rash or mucosal involvement.

Drug Interactions

Major Drug–Drug Interactions

1. Potassium‑sparing diuretics (e.g., spironolactone, amiloride) – increased risk of hyperkalemia.
2. ACE inhibitors and ARBs – additive effects on renal function and electrolyte balance.
3. Non‑steroidal anti‑inflammatory drugs (NSAIDs) – potential for decreased renal clearance.
4. Warfarin – potentiation of anticoagulant effect, increasing bleeding risk.
5. Antacids containing magnesium or aluminum – reduced absorption of cotrimoxazole.
6. Probenecid – decreased renal excretion, raising plasma concentrations.
7. Cimetidine – modest inhibition of hepatic metabolism, potentially increasing exposure.
8. Phenytoin and carbamazepine – induction of hepatic enzymes may lower cotrimoxazole levels.
9. Ketoconazole – competitive inhibition may increase serum concentrations.
10. Other sulfonamides – additive risk of hypersensitivity reactions.

Contraindications

Cotrimoxazole is contraindicated in patients with a documented hypersensitivity to sulfonamide antibiotics, a history of severe cutaneous reactions to trimethoprim or sulfamethoxazole, and in individuals with G6PD deficiency. Additionally, the drug is contraindicated during the first trimester of pregnancy, although some clinicians may consider its use after the first trimester in life‑threatening infections.

Special Considerations

Use in Pregnancy and Lactation

Trimethoprim crosses the placenta readily, whereas sulfamethoxazole demonstrates lower placental transfer. The potential teratogenic risk has led to the classification of cotrimoxazole as a category X drug during the first trimester. For patients beyond the first trimester, limited data suggest that the benefits may outweigh the risks in severe infections. During lactation, both agents are excreted into breast milk; therefore, nursing mothers are generally advised to discontinue cotrimoxazole unless the infant is at significant risk for infection.

Pediatric Considerations

In pediatric populations, dosing is weight‑based, typically 1 mg/kg of trimethoprim per dose, administered twice daily. Age‑specific pharmacokinetic data indicate a slightly shorter half‑life in infants compared to adults. The risk of hyperuricemia and nephrotoxicity is modest but warrants monitoring of renal function and serum uric acid levels. G6PD deficiency screening is recommended before initiating therapy in regions with high prevalence.

Geriatric Considerations

Older adults may exhibit reduced renal clearance, necessitating dose adjustment to avoid accumulation and toxicity. The incidence of adverse drug reactions, particularly rash and hematologic abnormalities, is higher in this demographic. Polypharmacy increases the likelihood of drug interactions; a thorough medication review is advisable.

Renal and Hepatic Impairment

Renal insufficiency profoundly influences drug exposure; dose reductions or extended dosing intervals are indicated based on creatinine clearance. Hepatic dysfunction has a limited effect on clearance, but caution is warranted due to potential accumulation of metabolites. In patients with severe hepatic impairment, the drug should be avoided unless no alternative exists.

Summary/Key Points

• Cotrimoxazole is a fixed‑dose combination of trimethoprim and sulfamethoxazole, acting synergistically to inhibit bacterial folate synthesis.
• Oral absorption is rapid; renal excretion dominates elimination with a half‑life of 8–12 hours.
• Approved indications include PCP, UTIs, and certain bacterial infections; off‑label uses are common in immunocompromised patients.
• Common adverse effects involve gastrointestinal upset, rash, and photosensitivity; serious reactions such as Stevens‑Johnson syndrome and G6PD‑related hemolysis are rare but severe.
• Drug interactions with potassium‑sparing diuretics, ACE inhibitors, NSAIDs, and warfarin are clinically significant and may necessitate dose adjustments.
• Special considerations include avoidance in pregnancy’s first trimester, careful dosing in renal impairment, and screening for G6PD deficiency in susceptible populations.
• Monitoring of renal function, serum electrolytes, and complete blood counts is recommended during therapy, especially in high‑risk groups.

Clinical pearls that may aid in the application of this monograph include maintaining the 1:4 ratio of trimethoprim to sulfamethoxazole, vigilant assessment for rash or mucosal involvement, and proactive collaboration with pharmacists when managing polypharmacy and potential interactions. Further studies are warranted to refine dosing strategies in special populations and to elucidate long‑term safety profiles.

References

1. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.
2. Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.
3. Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.
4. Brunton LL, Hilal-Dandan R, Knollmann BC. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 14th ed. New York: McGraw-Hill Education; 2023.
5. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.
6. Trevor AJ, Katzung BG, Kruidering-Hall M. Katzung & Trevor's Pharmacology: Examination & Board Review. 13th ed. New York: McGraw-Hill Education; 2022.
7. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.
8. Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.